A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Inclusion Criteria:

* The subject voluntarily agrees to participate and has signed the informed consent form.
* Male, aged ≥18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
* Life expectancy of at least 3 months.
* Histologically or cytologically confirmed adenocarcinoma of the prostate.
* Radiologically confirmed metastatic prostate cancer.
* For subjects with mCRPC, serum testosterone must be at castrate levels, and they must have demonstrated either PSA progression or radiographic progression.
* Must have undergone surgical castration or be willing to receive medical castration.
* For Phase Ib, subjects must have experienced failure, intolerance, or refusal of standard therapy.
* Adequate function of major organs as defined by the protocol.
* Agreement to use effective contraception during the study (except for subjects who have undergone bilateral orchiectomy).
* Sufficient blood samples must be provided during the screening period for genetic mutation testing.

Exclusion Criteria:

* Prior treatment with the following agents: AR PROTAC, abiraterone, enzalutamide, or B7H3-targeted therapies.
* Presence of central nervous system (CNS) metastases, leptomeningeal metastases, or spinal cord compression requiring hormonal therapy.
* Receipt of extensive radiotherapy within 4 weeks prior to the first administration of the investigational medicinal product.
* Treatment with other investigational drugs or major surgery within 4 weeks prior to the first administration of the investigational medicinal product.
* Presence of factors that may affect drug administration, intake, or absorption.
* History of epilepsy, or a condition that could provoke seizures within 12 months prior to the first administration of the investigational medicinal product.
* Known history of substance abuse, alcoholism, or drug addiction; or prior history of significant neurological or psychiatric disorders, including dementia or hepatic encephalopathy.
* Presence of severe cardiovascular or cerebrovascular disease.
* Active, uncontrolled infection.
* Clinically uncontrolled third-space fluid accumulation prior to the first administration of the investigational medicinal product.
* History of other malignancies within 5 years prior to the first administration of the investigational medicinal product.
* Presence of moderate to severe pulmonary disease that significantly impairs lung function.
* For subjects receiving QLC5508, history of non-infectious interstitial lung disease (ILD) or pneumonitis.